诺思格股价跌5.08%，东财基金旗下1只基金重仓，持有1.24万股浮亏损失3.48万元

Group 1 - The core point of the news is that Norscare's stock has experienced a decline of 5.08% on September 23, with a total market value of 5.072 billion yuan and a cumulative drop of 4.6% over the past four days [1] - Norscare (Beijing) Pharmaceutical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022. The company specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [1] - The revenue composition of Norscare's main business includes: clinical trial operation services (39.25%), clinical trial site management services (34.10%), data management and statistical analysis services (13.30%), biological sample testing services (8.45%), clinical pharmacology services (3.74%), and clinical trial consulting services (1.16%) [1] Group 2 - From the perspective of fund holdings, one fund under Dongcai has a significant position in Norscare, with Dongcai Vision Growth Mixed Initiation A (018088) holding 12,400 shares, accounting for 4.85% of the fund's net value, ranking as the fifth-largest holding [2] - The fund has experienced a floating loss of approximately 34,800 yuan today, with a cumulative floating loss of 33,100 yuan during the four-day decline [2] - Dongcai Vision Growth Mixed Initiation A (018088) was established on April 11, 2023, with a latest scale of 9.6956 million yuan, and has achieved a year-to-date return of 46.64% [2]